Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?

Bone Marrow Transplant. 2018 Nov;53(11):1487-1489. doi: 10.1038/s41409-018-0222-5. Epub 2018 Jun 8.

Authors

Avinash Bonda¹, Sachin Punatar¹, Anant Gokarn¹, Aniket Mohite¹, Kartthik Shanmugam¹, Lingaraj Nayak¹, Mounika Bopanna¹, Badira Cheriyalinkal Parambil¹, Navin Khattry²

Affiliations

¹ Stem cell transplant unit, Department of Medical Oncology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, India.
² Stem cell transplant unit, Department of Medical Oncology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, India. [email protected].

PMID: 29884853
DOI: 10.1038/s41409-018-0222-5

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Female
Humans
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

Substances

Antibodies, Monoclonal
daratumumab